知搜-全球专利检索

  1. 登录
  2. 注册
发明公开
CN109641051A 用于耗尽细胞的组合物和方法 审中-实审

用于耗尽细胞的组合物和方法
摘要：
本发明提供了可用于耗尽细胞诸如CD45+、CD135+、CD34+、CD90+和/或CD110+细胞，以及用于治疗尤其是多种造血系统疾病、代谢紊乱、癌症和自身免疫性疾病的组合物和方法。本文描述了抗体、抗原结合片段、配体及其缀合物，它们可以被应用于例如通过耗尽患者诸如人类中CD45+、CD135+、CD34+、CD90+、或CD110+细胞的群体来实现对这些状况的治疗。本文描述的组合物和方法可以用于例如通过耗尽CD45+、CD135+、CD34+、CD90+、或CD110+癌细胞或自身免疫性细胞的群体来直接治疗紊乱。本文描述的组合物和方法还可以用于为患者准备造血干细胞移植疗法，并且通过在移植程序之前选择性耗尽内源性造血干细胞来改善造血干细胞移植物的植入。
摘要（英）：

The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

0/0